Altering the Course of Disease Progression

 

Altering the Course of Disease Progression

 

Altering the Course of Disease Progression

Cortexyme Successfully Completes Acquisition of Novosteo

Cortexyme successfully completed the acquisition of Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury, on May [17], 2022. With the completion of the acquisition, the company appointed former Novosteo executives Dr. Dirk Thye as chief executive officer, and Dr. Karen Smith as chief medical officer of Cortexyme. Dr. Thye and Philip Low, PhD, also have been appointed to the Cortexyme’s Board of Directors.

Look Inside

Targeting the pathogenic cause of neurodegeneration

A unique and powerful approach.

Cortexyme is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients that causes neurodegeneration and other pathology in animal models. Additional programs are progressing in preclinical development.

Research

Testing

Results

Do you or someone you love have Alzheimer’s disease?

Learn about the GAIN Trial

Cortexyme in the news

June 21, 2022 in News

Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

SOUTH SAN FRANCISCO, Calif. – June 21, 2022 – Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics…
Read More
June 13, 2022 in News

Cortexyme Appoints June Bray to its Board of Directors

SOUTH SAN FRANCISCO, Calif. – June 13, 2022 – Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and…
Read More
May 20, 2022 in News

Cortexyme Appoints Dr. Philip Low to its Board of Directors

SOUTH SAN FRANCISCO, Calif. – May 20, 2022 – Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to…
Read More